MedPacto, Inc.

A235980

KR7235980000

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 03:30:00 10/05/2024 am IST			5-day change	1st Jan Change
9,010 ^KRW	-1.21%		-3.53%	+24.45%

2023	MedPacto, Inc. announced that it has received KRW 10.85806127 billion in funding from Theragen Etex Co.,Ltd.	CI
2023	South Korean Shares Nearly Unchanged Ahead of US Inflation Data	MT

MedPacto, Inc. announced that it has received KRW 70 billion in funding

January 15, 2021

On January 15, 2021, MedPacto, Inc. (KOSDAQ:A235980) closed the transaction.

Latest news about MedPacto, Inc.

MedPacto, Inc. announced that it has received KRW 10.85806127 billion in funding from Theragen Etex Co.,Ltd.	15/12	CI
South Korean Shares Nearly Unchanged Ahead of US Inflation Data	13/23/13	MT
Medpacto to Raise 115.9 Billion Won via Stock Sale	13/23/13	MT
MedPacto, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Medpacto, Inc. Appoints Timothy R. Allen as Executive Vice President	24/22/24	CI
MedPacto, Inc. announced that it has received KRW 30.0000844 billion in funding	15/21/15	CI
MedPacto, Inc. announced that it has received KRW 70 billion in funding	15/21/15	CI
MedPacto, Inc. announced that it expects to receive KRW 30.0000844 billion in funding	24/20/24	CI
MedPacto, Inc. announced that it expects to receive KRW 70 billion in funding	23/20/23	CI
MedPacto, Inc.(KOSDAQ:A235980) added to S&P Global BMI Index	22/20/22	CI
MedPacto, Inc. has completed an IPO in the amount of KRW 60.44 billion.	13/19/13	CI
MedPacto, Inc. has filed an IPO in the amount of KRW 72.48 billion.	13/19/13	CI
Medpacto, Inc. announced that it has received KRW 999.999 million in funding from UNO & COMPANY Ltd.	03/18/03	CI
Medpacto, Inc. announced that it expects to receive KRW 10,000 million in funding from UNO & COMPANY Ltd.	02/18/02	CI

MedPacto, Inc. is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company researches and develops anticancer drugs and diagnostic kits including vactosertib, MA-B2 and others. The products are used as the treatment of multiple myeloma, lung cancer, stomach cancer, colon cancer, blood cancer, triple negative breast cancer and pancreatic cancer, among others.

Sector

Biotechnology & Medical Research

Calendar

08/11/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MEDPACTO, INC.	+24.45%	221M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs

MedPacto, Inc.

Equities

A235980

KR7235980000

Biotechnology & Medical Research

MedPacto, Inc. announced that it has received KRW 70 billion in funding

Latest news about MedPacto, Inc.

Chart MedPacto, Inc.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs